NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.01. The company earned $0.56 million during the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 brokers have issued 12-month target prices for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $14.50 in the next year. This suggests a possible upside of 213.9% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Media coverage about SYRS stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a decline in short interest in November. As of November 29th, there was short interest totalling 1,850,000 shares, a decline of 15.9% from the November 14th total of 2,200,000 shares. Based on an average daily volume of 262,900 shares, the short-interest ratio is presently 7.0 days. Approximately 6.0% of the company's shares are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include CannTrust (CNTTF), Stoke Therapeutics (STOK), Aprea Therapeutics (APRE), Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), ANI Pharmaceuticals (ANIP), Urogen Pharma (URGN), Kiniksa Pharmaceuticals (KNSA), Collegium Pharmaceutical (COLL), Intra-Cellular Therapies (ITCI), Kura Oncology (KURA), Omeros (OMER), Akero Therapeutics (AKRO), Cara Therapeutics (CARA) and Axovant Sciences (AXON).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD) and Global Blood Therapeutics (GBT).

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.92%), Sumitomo Mitsui Trust Holdings Inc. (10.92%), Redmile Group LLC (9.16%), State Street Corp (1.59%), Millennium Management LLC (0.04%) and Barclays PLC (0.04%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

SYRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young and Venture Fund Vii LP Arch. View Insider Buying and Selling for Syros Pharmaceuticals.

SYRS stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Redmile Group LLC, State Street Corp, Millennium Management LLC, Metropolitan Life Insurance Co NY and Tower Research Capital LLC TRC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $4.62.

Syros Pharmaceuticals has a market capitalization of $196.07 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]